Table 3 Mediation analysis of the effect of lipid-lowering agents on IBD risk via potential mediators
Exposure | Adjustment | Outcome | Indirect effects estimate (95% CI) | P Value | Median proposition (%) (95%CI) |
|---|---|---|---|---|---|
APOC3 | Family_ Clostridiumsensustricto1 | IBD | -0.03(-0.06, 0) | 7.30E-03 | 17.39(14.34–20.44) |
APOC3 | Family_ Clostridiaceae1 | IBD | -0.03(-0.06, -0.01) | 2.70E-03 | 20.06(16.91–23.22) |
APOC3 | Group_ LachnospiraceaeFCS020group | IBD | 0.017(0, 0.04) | 3.34E-02 | 12.05(10.08–14.01) |
LDLR | Family_ Lactobacillaceae | IBD | 0.04(0.01, 0.09) | 4.55E-02 | 17.83(12.16–23.5) |
APOC3 | Family_ Clostridiumsensustricto1 | UC | -0.028(-0.06, 0.04) | 0.061 | 14.77(10.46–19.08) |
APOC3 | Order_Bacillales | UC | -0.031(-0.07, 0.04) | 0.081 | 15.01(9.67–20.35) |
LPL | Group_ RuminococcaceaeUCG009 | CD | 0.03(0, 0.07) | 0.064 | 13.67(9.93–17.41) |